

3. A novel polypeptide having an amino acid sequence of natural human Fas ligand wherein all of the 8th amino acid to 69th amino acid residues as measured from N terminal end are deleted, 129th amino acid and 130th amino acid residues as measured from N terminal end are both deleted or substituted, and at least one amino acid residue from 111th amino acid to 128th amino acid residues or at least one amino acid residues from 131st amino acid to 133rd amino acid residues as measured from N terminal end is deleted or substituted.

10. A novel polypeptide having an amino acid sequence of natural human Fas ligand wherein the 129th amino acid and 130th amino acid residues as measured from N terminal end are both deleted or substituted, and at least one amino acid residue from 111th amino acid to 128th amino acid residues or at least one amino acid residue from 131st amino acid to 133rd amino acid residues as measured from N terminal end is deleted or substituted, wherein said novel polypeptide has membrane binding activity and induces Fas-mediated apoptotic activity.

11. A novel polypeptide having an amino acid sequence of natural human Fas ligand wherein all of the 8th amino acid to 69th amino acid residues as measured from N terminal end are deleted, 129th amino acid and 130th amino acid residues as measured from N terminal end are both deleted or substituted, and at least one

Sub
831 amino acid residue from 111th amino acid to 128th amino acid residues or at least one amino acid residues from 131st amino acid to 133rd amino acid residues as measured from N terminal end is deleted or substituted wherein said novel polypeptide has membrane binding activity and induces Fas-mediated apoptotic activity.
